In the Claims:

1. (Currently amended) A compound of the formula (I)

wherein,

R1 is hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R2 is hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms or OH,

R3 is hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms or OH,

is a 9- or a 10-membered bicyclic heteroaryl-having one, two or three nitrogen atoms-7H-pyrrolo-[2,3-d]-pyrimidine, which may be linked via any of its positions and which is substituted in at least one of its positions by alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, nitro, NRaRb, alkylcarbonylamino having 1, 2, 3 or 4 carbon atoms, hydroxyl, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms, S(O)_nR4, CO₂H, alkoxycarbonyl having 1, 2, 3, 4, 5 or 6 carbon atoms, alkylcarbonyl having 1, 2, 3, 4, 5 or 6 carbon atoms, CONRaRb, CN, polyfluoroalkyl having 1, 2, 3 or 4 carbon atoms, polyfluoroalkoxy having 1, 2 or 3 carbon atoms or SO₃H, n = 0, 1 or 2,

Ra and Rb

are independently of each other hydrogen, linear or branched alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or Ra and Rb form, together with the nitrogen atom to which they are attached, a 5- or 6-membered heterocycle, which may optionally contain another hetero atom chosen from O, S and N,

R4 is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, alkylamino having 1, 2, 3, 4, 5 or 6 carbon atoms or NH₂,

or a racemic mixture, enantiomer, diastereomer, or tautomer of such compound, or a mixture thereof, or a pharmaceutically acceptable salt of such compound, racemic mixture, enantiomer, diastereomer, tautomer, or mixture.

2. (cancelled)

- 3. (Currently amended) A compound according to claim 1 wherein:
 - R1 is hydrogen or alkyl-having 1, 2, 3, 4, 5 or 6 carbon atoms,
 - R2—is hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms or OH,
 - R3 is hydrogen or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms or OH,
 - Ar is 4-quinolinyl, 4-quinazolinyl-or-4-(7H-pyrrolo-[2,3-d]-pyrimidinyl), which is substituted in at least one of its positions by alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, halogen, nitro, NRaRb, alkylcarbonylamino having 1, 2, 3 or 4 carbon atoms, hydroxyl, alkoxy having 1, 2, 3, 4, 5 or 6 carbon atoms, S(O)_nR4, CO₂H, alkoxycarbonyl having 1, 2, 3, 4, 5 or 6 carbon atoms, alkylcarbonyl having 1, 2, 3, 4, 5 or 6 carbon atoms, CONRaRb, CN, polyfluoroalkyl having 1, 2, 3 or 4 carbon atoms, polyfluoroalkoxy having 1, 2 or 3 carbon atoms or SO₃H₅

-n=0, 1 or 2,

Ra and Rb

are independent of each other hydrogen, linear or branched alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or Ra and Rb form, together with the nitrogen atom to which they are attached, a 5- or 6 membered heterocycle, which may optionally contain another hetero atom chosen from O, S and N,

- R4 is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, alkylamino having 1, 2, 3, 4, 5 or 6 carbon atoms or NH₂
- 4. (Currently amended) A compound according to claim 1 which is
 - 3-Guanidinocarbonyl-1-(2-(trifluoromethyl)quinol-4-yl)-1H-indole,
 - 3-Guanidinocarbonyl-1-(6-(trifluoromethyl)quinol-4-yl)-1H-indole;
 - 3-Guanidinocarbonyl-1-(7-(trifluoromethyl)quinol-4-yl)-HH-indole,

- 3 Guanidinocarbonyl-1 (8 (trifluoromethyl)quinol-4-yl)-1H-indole,
- 3-Guanidinocarbonyl 1 (6-methoxyquinol 4-yl) 1H-indole,
- 3-Guanidinocarbonyl-1 (7-methoxyquinol-4-yl) IH-indole,
- 3 Guanidinocarbonyl-1 (2 methylquinol 4 yl) 111 indole.
- 3-Guanidinocarbonyl 1 (6 chloroquinol 4 yl) 111 indole,
- 3-Guanidinocarbonyl-1-(7-chloroguinol-4-yl)-1H-indole,
- 3 Guanidinocarbonyl-1 (8 chloroquinol-4-yl) 1H indole,
- 3-Guanidinocarbonyl-1 (6-fluoroquinol-4-yl)-111-indole,
- 3-Guanidinocarbonyl-1 (8-fluoroquinol-4-yl)-111-indole,
- 3-Guanidinocarbonyl-1-(6,8-difluoroquinol-4-yl)-1H-indole,
- 3-Guanidinocarbonyl-1-(6-fluoro-2-methylquinol-4-yl)-HI-indole,
- 3-Guanidinocarbonyl 1 (7-fluoro 2 methylquinol 4 yl) H1 indole,
- 3 Guanidinocarbonyl-1 (8 fluoro-2 methylquinol-4 yl) 1H indole,
- 3-Guanidinocarbonyl-1-(7-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-indole,
- 3-Guanidinocarbonyl-1-(7-chloroquinol-4-yl)-5-methoxy-2-methyl-1H-indole.
- 3-Guanidinocarbonyl-1 (6-fluoroquinol-4-yl)-5-methoxy-2-methyl-1H-indole, or
- 3-Guanidinocarbonyl-1 (6-chloro-quinazolin-4-yl) 5-methoxy-2-methyl-1H-indole, or a tautomer thereof or a pharmaceutically acceptable salt of such compound or tautomer.
- (Original) A pharmaceutical composition for human, veterinary, or phytoprotective
 use comprising a pharmaceutically effective amount of a compound according to claim
 1 together with a pharmaceutically acceptable medium.
- 6. (Original) A pharmaceutical composition for human, veterinary, or phytoprotective use comprising a pharmaceutically effective amount of a compound according to claim 1 together with a pharmaceutically acceptable medium in combination with a pharmaceutically effective amount of another pharmacologically active ingredient or medicament.
- 7. (Withdrawn) A method for the treatment or prophylaxis of cardiovascular disease, metabolic disease, cancerous disease, or fibrotic disease comprising administering to a

patient in need thereof, a pharmaceutically effective amount of a compound according to claim 1.

- 8. (Withdrawn) A method for the treatment or prophylaxis of acute or chronic damage to, or disorders or indirect sequelae of organs and tissues caused by ischemic or reperfusion events; arrhythmias, life-threatening cardiac ventricular fibrillation, myocardial infarction, angina pectoris; ischemic states of the heart, ischemic states of the peripheral and central nervous system, stroke, cerebral oedema attack, ischemic states of peripheral organs and tissues; states of shock; diseases in which cellular proliferation represents a primary or secondary cause; cancer, metastasis, prostate hypertrophy, prostate hyperplasia; atherosclerosis, disturbances of lipid metabolism, high blood pressure; disorders of the central nervous system; non-insulin-dependent diabetes mellitus, late damage from diabetes; thromboses, disorders resulting from endothelial dysfunction, intermittent claudication; fibrotic disorders of internal organs, fibrotic disorders of the liver, fibrotic disorders of the kidney, fibrotic disorders of vessels, fibrotic disorders of lung, fibrotic disorders of the heart; heart failure, congestive heart failure, acute or chronic inflammatory disorders, disorders caused by protozoa; malaria, or coccidiosis in poultry, comprising administering to a patient in need thereof, a pharmaceutically effective amount of a compound according to claim 1.
- 9. (Withdrawn) A method according to claim 8 for the treatment or prophylaxis of allergic shock, cardiogenic shock, hypovolaemic shock or bacterial shock.
- (Withdrawn) A method according to claim 8 for the treatment or prophylaxis of essential hypertension.
- 11. (Withdrawn) A method according to claim 8 for the treatment or prophylaxis of disorders resulting from overexcitability of the CNS.
- 12. (Withdrawn) A method according to claim 11, for the treatment or prophylaxis of epilepsy or centrally induced convulsions.
- 13. (Withdrawn) A method according to claim 8 for the treatment or prophylaxis of

anxiety states, depressions or psychoses.

- 14. (Withdrawn) A method for protecting an organ in a transplant donor during organ transplantation, both before and during the removal of the organ, comprising administering to said donor, a pharmaceutically effective amount of a compound according to claim 1.
- 15. (Withdrawn) A method for protecting a removed organ during treatment with, or storage in physiological bath liquids, comprising contacting said organ with a compound according to claim 1.
- 16. (Withdrawn) A method for protecting a removed organ during transfer to a recipient organism during organ transplantation, comprising contacting said organ with a compound according to claim 1.
- 17. (Withdrawn) A method for preventing age-related tissue change, in a patient in need thereof, comprising administering to said patient, a pharmaceutically effective amount of a compound according to claim 1.
- 18. (Withdrawn) A method for prolonging life in a patient in need thereof, comprising administering to said patient, a pharmaceutically effective amount of a compound according to claim 1.
- 19. (Withdrawn) A method for the treatment or reduction of the cardiotoxic effects in thyrotoxicosis in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1.
- 20. (Original) A diagnostic agent comprising a compound according to claim 1.
- 21. (Withdrawn) A method for the treatment or prophylaxis of acute or chronic damage to, or disorders or indirect sequelae of organs and tissues caused by ischemic or reperfusion events; arrhythmias, life-threatening cardiac ventricular fibrillation, myocardial infarction, angina pectoris; ischemic states of the heart, ischemic states of the peripheral and

central nervous system, stroke, cerebral oedema attack, ischemic states of peripheral organs and tissues; states of shock; diseases in which cellular proliferation represents a primary or secondary cause; cancer, metastasis, prostate hypertrophy, prostate hyperplasia; atherosclerosis, disturbances of lipid metabolism, high blood pressure; disorders of the central nervous system; non-insulin-dependent diabetes mellitus, late damage from diabetes; thromboses, disorders resulting from endothelial dysfunction, intermittent claudication; fibrotic disorders of internal organs, fibrotic disorders of the liver, fibrotic disorders of the kidney, fibrotic disorders of vessels, fibrotic disorders of lung, fibrotic disorders of the heart; heart failure, congestive heart failure, acute or chronic inflammatory disorders, disorders caused by protozoa; malaria, or coccidiosis in poultry, comprising administering to a patient in need thereof, a pharmaceutically effective amount of a compound according to claim 1, in combination with a pharmaceutically effective amount of another medicament or active ingredient.

- 22. (Withdrawn) A method according to claim 21 for the treatment or prophylaxis of allergic shock, cardiogenic shock, hypovolaemic shock or bacterial shock.
- (Withdrawn) A method according to claim 21 for the treatment or prophylaxis of essential hypertension.
- 24. (Withdrawn) A method according to claim 21 for the treatment or prophylaxis of disorders resulting from overexcitability of the CNS.
- (Withdrawn) A method according to claim 24, for the treatment or prophylaxis of epilepsy or centrally induced convulsions.
- (Withdrawn) A method according to claim 21 for the treatment or prophylaxis of anxiety states, depressions or psychoses.
- 27. (Withdrawn) A method for protecting an organ in a transplant donor during organ transplantation, both before and during the removal of the organ, comprising administering to said donor, a pharmaceutically effective amount of a compound

- according to claim 1 in combination with a pharmaceutically effective amount of another medicament or active ingredient.
- 28. (Withdrawn) A method for protecting a removed organ during treatment with, or storage in physiological bath liquids, comprising contacting said organ with a compound according to claim 1 in combination with another medicament or active ingredient.
- 29. (Withdrawn) A method for protecting a removed organ during transfer to a recipient organism during organ transplantation, comprising contacting said organ with a compound according to claim 1 in combination with another medicament or active ingredient.
- 30. (Withdrawn) A method for preventing age-related tissue change, in a patient in need thereof, comprising administering to said patient, a pharmaceutically effective amount of a compound according to claim 1 in combination with a pharmaceutically effective amount of another medicament or active ingredient.
- 31. (Withdrawn) A method for prolonging life in a patient in need thereof, comprising administering to said patient, a pharmaceutically effective amount of a compound according to claim 1 in combination with a pharmaceutically effective amount of another medicament or active ingredient.
- 32. (Withdrawn) A method for the treatment or reduction of the cardiotoxic effects in thyrotoxicosis in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1 in combination with a pharmaceutically effective amount of another medicament or active ingredient.
- 33. (Original) A diagnostic agent comprising a compound according to claim 1 in combination with an another medicament or active ingredient.
- 34. (Withdrawn) A method of reducing the cardiotoxic or cytotoxic effects of cardiotoxic or cytotoxic medicaments or active ingredients having cardiotoxic or cytotoxic properties, in a patient in need thereof, comprising administering to said patient, a

pharmaceutically effective amount of a compound according to claim 1 in combination with a pharmaceutically effective amount of said cardiotoxic or cytotoxic medicament or active ingredient.

- 35. (Withdrawn) A method for the treatment or prophylaxis of acute or chronic damage, disorders or indirect sequelae of organs or tissues caused by ischemic or reperfusion events in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1.
- 36. (Withdrawn) A method for the treatment or prophylaxis of acute or chronic damage, disorders or indirect sequelae of organs or tissues caused by ischemic or reperfusion events in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1 in combination with a pharmaceutically effective amount of another medicament or active ingredient.
- 37. (Withdrawn) A method for the treatment of life-threatening cardiac ventricular fibrillation, in a patient in need thereof, comprising comprising administering to said patient, a pharmaceutically effective amount of a compound according to claim 1.
- 38. (Withdrawn) A method for the treatment of life-threatening cardiac ventricular fibrillation, in a patient in need thereof, comprising comprising administering to said patient, a pharmaceutically effective amount of a compound according to claim 1 in combination with a pharmaceutically effective amount of another medicament or active ingredient.
- 39. (Withdrawn) A method for the treatment or prophylaxis of metastasis in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1.
- 40. (Withdrawn) A method for the treatment or prophylaxis of metastasis in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1 in combination with a pharmaceutically effective amount of another medicament or active ingredient.

- 41. (Withdrawn) A method for the treatment or prophylaxis of fibrotic disorders of the heart, heart failure, or congestive heart failure, in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1.
- 42. (Withdrawn) A method for the treatment or prophylaxis of fibrotic disorders of the heart, heart failure, or congestive heart failure, in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1 in combination with a pharmaceutically effective amount of another medicament or active ingredient.
- 43. (Withdrawn) A method for the treatment or prophylaxis of a disease which is related to NHE, in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1.
- 44. (Withdrawn) A method for the treatment or prophylaxis of a disease which is related to NHE, in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1 in combination with an effective amount of another medicament or active ingredient.
- 45. (Withdrawn) A method for the treatment or prophylaxis of a disease which is related to NHE1, in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1.
- 46. (Withdrawn) A method for the treatment or prophylaxis of a disease which is related to NHE1, in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound according to claim 1 in combination with a pharmaceutically effective amount of another medicament or active ingredient.
- 47. (Withdrawn) A method for protecting the organs or blood vessels during surgical intervention, in a patient in need thereof, comprising administering to such patient a pharmaceutically effective amount of a compound according to claim 1.
- 48. (Withdrawn) A process for the preparation of a compound according to claim 1,

comprising

RO
$$\begin{array}{c}
R2 \\
R1
\end{array}$$

$$\begin{array}{c}
R1
\end{array}$$

$$\begin{array}{c}
R2 \\
R1$$

$$\begin{array}{c}
R2 \\
R1
\end{array}$$

$$\begin{array}{c}
R2 \\
R1
\end{array}$$

$$\begin{array}{c}
R2 \\
R1
\end{array}$$

$$\begin{array}{c}
R2 \\
R1$$

$$\begin{array}{c}
R2 \\
R1
\end{array}$$

$$\begin{array}{c}
R2 \\
R1
\end{array}$$

- a) reacting a heteroaryl halide ArX of the formula (VI) with a 3-alkoxycarbonyl-1H-indole of the formula (II);
- b) saponifying the obtained 3-alkoxycarbonyl-1-heteroaryl-indole of the formula (III);
- c) converting the obtained 3-carboxy-1-heteroaryl-indole of the formula (IV) to the corresponding acid chloride of the formula (V);
- d) reacting the acid chloride of formula (V) with guanidine, and isolating the compound according to claim 1; and optionally converting it into a pharmaceutically acceptable salt thereof,

wherein in the compounds of the formula II, III, IV, V and VI

Ar and R1 to R3 are defined as in claim 1,

X is F, Cl, Br or I and

R is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms.